Hence, the natural terpenoid compound, 27-deoxyactein, holds promise as a strong candidate for inhibiting MDM2, warranting further investigation as a lead compound in experimental and clinical studies to enhance breast cancer treatment efforts. The gene discussed is MDM2; the disease is breast carcinoma.